Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.
Authors
- Daniel A. Goldstein (ORCID: https://orcid.org/0000-0002-8082-9622)
- Leonard B. Saltz (ORCID: https://orcid.org/0000-0001-8353-4670)
- Mark J. Ratain (ORCID: https://orcid.org/0000-0002-0938-4392)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2024-08-29
- DOI
- https://doi.org/10.17615/eybe-wc94
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00